Introduction {#s0005}
============

Sarcoidosis is a multisystemic immune disorder of unknown aetiology that was first described as a separate medical condition in 1877. The disease is characterized by the formation of non-caseating epithelioid cell granulomas in involved organs. It has a worldwide incidence and it commonly affects young and middle-aged individuals between the ages of 20 and 40 years while later onset of the disease is not unusual. The incidence is estimated at around 16.5/100.000 in men and 19/100.000 in women; being higher in women and in people of African origin ([@bb0030], [@bb0060], [@bb0070], [@bb0115]). The lung and the lymphatic system are predominately affected but virtually every organ may be involved ([@bb0065], [@bb0115]). Lung involvement alone is present in 86%--92% of cases or in association with extra-pulmonary localizations in about 50% of cases ([@bb0120]). One-third or more of patients are asymptomatic, with incidental abnormalities on chest radiographs ([@bb0085]). Most frequently affected extra-pulmonary sites include the skin, eyes, liver, lymph nodes, heart and central nervous system (CNS; [@bb0025], [@bb0115]). The clinical course and expression of pulmonary sarcoidosis is variable. In at least half of cases, a benign course is followed with spontaneous resolution within less than 12--36 months, while in up to 30% of patients, the course is chronic ([@bb0085], [@bb0120]). When sarcoidosis affects the skin, eyes, or liver, it causes significant morbidity ([@bb0130]). Mortality is estimated between 0.5% and 5% with severe disease leading to respiratory insufficiency and death from pulmonary or cardiac complications ([@bb0115]). Clinical evidence of cardiac sarcoidosis has been reported in only 10% of patients, underscoring the importance of early detection^.^([@bb0090]).

Diagnosis can be established when typical clinical-radiological findings are supported by histologic evidence of epithelioid granulomas in more than one organ system and by exclusion of other disorders known to cause granulomatous disease ([@bb0010], [@bb0030], [@bb0060]).

The etiology of sarcoidosis is unknown. Both environmental and hereditary factors have been proposed, supported by reports of familial clustering and associations between sarcoidosis and genetic polymorphisms ([@bb0140], [@bb0155]). It seems that the development of sarcoidosis is probably the end result of exogenous agents (viruses and bacteria) acting on a genetically susceptible background triggering an immune response and leading to the formation of pathognomic granulomas ([@bb0025], [@bb0070], [@bb0150]).

The immune response in sarcoidosis is primarily mediated by the accumulation of activated CD4 + T-cells of the Th1 type and macrophages at sites of ongoing inflammation, notably in the lung. Cytokines and other mediators produced by these cells contribute to granuloma formation ([@bb0025], [@bb0155]). The proinflammatory macrophage cytokines IL-1, IL-6 and TNF-a are essential to induce and maintain granuloma formation, and all are increased in sarcoidosis, whereas the anti-inflammatory cytokine IL-10 is associated with resolution of the granuloma, suppressing the inflammatory response ([@bb0175]).

In addition to cytokines and their receptors, other cell-signaling molecules are involved in regulating immune responses. Associations between class I HLA-B8 antigens and acute sarcoidosis ([@bb0040]) and HLA class II antigens are reported ([@bb0050], [@bb0055]). Valentonyte et al. ([@bb0165]) reported an association of the butyrophilin-like 2 (*BTNL2*) gene on chromosome 6p21.32 (OMIM \#612387) with sarcoidosis, and others have confirmed this association in African Americans and Whites ([@bb0135], [@bb0145]). The *BTNL2* gene is a member of the immunoglobulin gene superfamily (B7 receptor family) resides in the class II major histocompatibility complex (MHC) region of chromosome 6p and is expressed on activated B and T cells. *BTNL2* appears to regulate T-cell activation, implicating the gene in inflammatory autoimmune diseases ([@bb0080], [@bb0095], [@bb0110], [@bb0160]).

Given previous publications of the association of a specific SNP (rs2076530; [@bb0075], [@bb0100], [@bb0165], [@bb0170]) in the *BTNL2* gene and sarcoidosis, we sequenced all exons and adjoining intronic regions of the *BTNL2* gene (ENSG00000224242.3, gene sequence:NM_019602.1) on a clinically well-characterized cohort of Greek patients with sarcoidosis and a control population. Our aim was to replicate previously published results indicating *BTNL2* gene variants as risk alleles for sarcoidosis in the Greek population and also investigate their association with specific disease phenotypic features and prognosis.

Materials and methods {#s0010}
=====================

Patients {#s0015}
--------

This was a case-control study. The patient group consisted of (a) 146 Greek sarcoidosis patients (56 males and 90 females with mean age 46 ± 12.7; range, 21--73 years), with mean age of disease onset 43.1 ± 13.3 and (b) a general population control group (*n* = 90; 37 males and 53 females with a mean age of 46 ± 18.4; range, 18--77 years). The average time for observation for all patients was 5 years. There were no familiar sarcoidosis cases. The control group consisted of healthy volunteers. None of the controls had a history of pulmonary or other inflammatory disease.

Whole blood samples from the patients were obtained from the Outpatient Clinic of the Respiratory Department of the University of Athens and the 8th Department of Respiratory Medicine of the "Sotiria" Chest Disease Hospital of Athens. In all patients, the diagnosis of sarcoidosis was established by typical clinical and radiological findings and in many cases supported by histological evidence of non-caseating epithelioid cell granulomas in affected tissue/organ. Detailed clinical data of the patient populations are shown in [Table 1](#t0005){ref-type="table"}.

All individuals included in the study were of Greek origin. The study was approved by the Ethics Committee of the University of Athens and all subjects participating signed an informed consent.

DNA extraction {#s0020}
--------------

Genomic DNA was extracted from 3 ml of peripheral blood, using the commercially available kit Nucleospin Blood L (MACHEREY-NAGE).

BTNL2 gene {#s0025}
----------

Butyrophyillin-like-2 (MCH class II associated) *BTNL2* (MIM: 606000, Gene ID:56244) sequences were downloaded from Ensembl Genome Browser ([www.ensemble.org/index.html](http://www.ensemble.org/index.html){#ir0020}; gene sequence ENST0000022424.3; NM_019602.1).

The presence of mutations in the 6 exons and neighboring intronic regions (50--150 bp on each side of each exon) of the *BTNL2* gene was assessed by Sanger sequencing. Sequencing analysis was performed with the DYEnamic^TM^ dye terminator kit-Megabase (GE HealthCare LLC), run on the Megabase 1000/4000 series automated sequencer (GE HealthCare, LLC) and analyzed with the BioEdit software. The primers were designed using Primer 3 (primer sequences are shown in [Supplementary Table 1](#ec0005){ref-type="supplementary-material"}).

Mutation evaluation {#s0030}
-------------------

The sequence of the gene including known variations were downloaded from <http://www.ensembl.org/Homo_sapiens/Transcript/Variation_Transcript/>. With the use of bioinformatics tools such as SIFT ([@bb0105]), PolyPhen-2 ([@bb0005]), PMut ([@bb0035]), PROVEAN ([@bb0015]) and EX_Skip ([@bb0125]) in combination with the clinical phenotype, we have attempted to elucidate the effect of these variants, including the novel ones found in this study.

Statistical analysis {#s0035}
--------------------

Statistical analysis was performed using SPSS 17.0, *p* values were calculated using double-sided Fisher\'s test (significant *p* values \< 0.05).

Results and discussion {#s0040}
======================

The present study examined the entire coding sequence and neighboring intronic regions of the *BTNL2* gene in 146 patients with sarcoidosis and in 90 healthy controls of the same ethnic origin. Thirty-seven different variants were detected from which 12 were synonymous substitutions and 25 were non-synonymous. In addition, 16 intronic variants were detected ([Supplementary Table 2](#ec0010){ref-type="supplementary-material"}), from which 7 were novel. Overall, the intronic variants showed similar frequencies between cases and controls. The majority of individuals from both groups carried more than one variant with 31.5% of cases and 44.4% of controls having the wild type sequence for all regions sequenced.

We used *in silico* tools (SIFT, PolyPhen, PROVEAN, PMut and EX_SKIP; [@bb0005], [@bb0015], [@bb0035], [@bb0105], [@bb0125]) to classify the variants as benign or pathological and EX_SKIP to determine if they affected exon skipping. If more than 2 of the SIFT, PolyPhen, PROVEAN, and PMut tools classified the variant as deleterious, pathological or possibly damaging, we considered them as being possible risk variants.

Amongst the non-synonymous substitutions, six were novel, p.A142P, p.S149T, p.E242G, p.S406A, p.G412C and p.A430D (not reported in the HGMD: <http://www.hgmd.org/>), and were not found in the control group. One heterozygote for the minor allele was detected for the novel variants p.A142P, p.S149T, p.E242G and p.A430D while for p.S406A and p.G412C, two heterozygotes were found amongst the patient group.

The *in silico* evaluation characterized variants p.D118N, p.A142P, p.G143D, p.T165I, p.E242G, p.S334L, p.G412C, p.A430D and p.E454C as conferring possible risk causing changes in the structure and function of the produced protein, and probably contributing to the clinical phenotype along with other genetic or environmental causes. Additionally, 15 variants, amongst them 3 novel, 5 synonymous, and the known splicing allele p.S360G (rs2076530), were identified as causing exon skipping by the EX_SKIP software ([Table 2](#t0010){ref-type="table"}). More specifically, heterozygosity for the known sarcoidosis risk splicing variant p.S360G (rs2076530; [@bb0075], [@bb0100], [@bb0165], [@bb0170]) was frequent in both cases (37.67%) and controls (30%) showing a higher frequency of homozygotes for the ancestral allele (G) amongst the control group (13.3% vs. 3.42%; *p* = 0.0062) rather than the sarcoidosis patients. Significant statistical difference in frequency of heterozygotes for the minor allele between cases and controls was found for p.H60H (*p* = 0.045) and p.W94R (*p* = 0.0088). Variant p.H60H, although synonymous, was identified probably causing exon skipping by EX_SKIP ([Table 2](#t0010){ref-type="table"}).

Amongst the 146 patients, 27 presented with Löfgren syndrome (a benign form of sarcoidosis), eleven of which carried possible risk variants. The clinical characteristics of patients carrying either novel or previously reported variants deemed possible risk variants and/or affecting splicing are shown in [Table 3](#t0015){ref-type="table"}. In general, the patients carrying the novel variants (cases 119, 2019, 274, 77 and 239; [Table 3](#t0015){ref-type="table"}), either alone or in combination with other risk variants, presented with mild lung disease (stage 0 or I) and good response to treatment, except for the one carrying p.E242G, which developed stage II pulmonary sarcoidosis with relapses. All, however, presented with extra-pulmonary manifestations as well.

Previous studies have implicated rs2076530 (p.S360G) as a risk allele for autoimmune inflammatory diseases such as sarcoidosis and myositis, although the immunological basis of this association is not yet clear ([@bb0075], [@bb0100], [@bb0165], [@bb0170]). The same variant was also frequently found in both the Greek cases and controls ([Table 2](#t0010){ref-type="table"}) agreeing with previous studies ([@bb0100], [@bb0135]). The second most common "possible risk variant" as characterized by the *in silico* study for the Greek population was p.S334L (15.75%), with another 11 nonsynonymous "possible risk variants" \[p.D118N (cases 2019 and 114), p.A142P (2019), p.G143D (90), p.T165I (103, 163), p.A202V (63, 2028, 2023, 90, 163, 181, 21), p.E242G (239), p.D283V (63, 103, 163), p.M295V (103), p.G412C (274, 77), p.A430D (119) and p.E454C (63, 103, 163, 49)\], found in 1 to 4 cases; the majority in combination with other risk variants ([Table 3](#t0015){ref-type="table"}).

Studying the coinheritance of other risk variants in the 60 patients carrying rs2076530, we found that five also carried p.A202V. The largest proportion of these (4/5, 80%) had chronic disease with relapses, pulmonary hypertension, calciuria and cardiac complications. However, a patient with Löfgren syndrome (case 90), a benign form of the disease, was compound heterozygote for p.G143D, p.A202V and p.S360G, perhaps moderating the expression of the disease. Detection of p.A202V in homozygosity (case 21) in the absence of any other risk variants was associated with mild lung disease but in combination with relapses and exo-pulmonary complications. While the combination of p.D118N, p.A142P and p.S360G (case 2019) presented with mild lung disease, normal DLCO and parotid gland swelling, while the coinheritance of p.A430D and p.S360G (case 119) resulted in mild pulmonary disease with hypercalciuria and uveitis. Five p.S360G homozygotes (168, 56, 178, 165) with one also coinheriting 4 other risk variants (163) were detected. Four of these p.S360G homozygotes presented with mild pulmonary disease while case 163 presented with stage II disease accompanied by extra-pulmonary complications and relapses. One might conclude that the coinheritance of more than one risk variant contributed to the more severe phenotype ([Table 3](#t0015){ref-type="table"}).

From the total of 146 sarcoidosis cases, we had a follow-up duration for five years on average for 121. They were divided into two subgroups. Subgroup A consisting of 81 patients with non-persistent pulmonary disease stage 0 or I, including 11 patients with Löfgren syndrome and subgroup B composed of 40 patients with persistent pulmonary disease stage II, III or IV. The most common variant p.S360G (rs2076530) was detected in 37 patients (45.7%) in subgroup A and in 12 patients (30%) in subgroup B.

The second most common variant p.S334L was detected in heterozygosity with no other risk variants in 19 cases, the majority of which had stage II or III pulmonary disease and almost all presented extra-pulmonary manifestations and relapses. A homozygous p.S334L case (235) presented with stage III disease, relapses and extra-pulmonary complications with a large proportion having skin granulomas. Perhaps the inheritance of this variant in patients with sarcoidosis increases the likelihood of skin manifestations. Variant p.S334L coinherited with p.S360G (104, 19) was also associated with severe pulmonary disease with relapses, heart and skin symptoms, while case 103 with the variant combination: p.S334L, p.T165I, p.D283V, p.E454C, and p.M295V had Löfgren syndrome with spontaneous recovery without therapy. The additional coinheritance of the other risk variants could act as disease modifiers ([Table 3](#t0015){ref-type="table"}).

Finally, variant p.E454C alone or together with others could be characterized as a risk allele related to chronic disease with relapses, pulmonary hypertension, hypercalciuria and hypercalcemia.

One of the limitations of our study is the small number of cases and controls; however, a major strength is that the cases and controls were of the same ethnic origin, avoiding population stratification. Additionally, the cases were well characterized clinically into different sarcoidosis disease stages. Finally, none of the previous studies had sequenced the whole coding region of the *BTNL2* gene.

Conclusions {#s0045}
===========

The clinical phenotypes of complex diseases are most likely due to the interaction between multiple causative or contributory alleles, as well as non-genetic determinants ([@bb0020]). Sarcoidosis being a multifactorial/complex disorder, the requirement for genetic risk alleles in many genes and/or environmental factors has been proven to be necessary for the disease to manifest clinically ([@bb0045]). In this case control study, the combinations of multiple causative or contributory risk variants in the *BTNL2* gene, implicated in the causation of sarcoidosis, were found to affect the final clinical phenotype of the disease with p.S360G and p.S334L contributing to a more severe disease stage with extra-pulmonary manifestations such as skin granulomas and relapses.

The following are the supplementary data related to this article.Supplementary Table 1PCR primers for the *BTNL2* geneSupplementary Table 2Intronic variants in the *BTNL2* gene in cases and controls

This article is dedicated to the memory of Panagiota Latsi who inspired and motivated us all to investigate pulmonary diseases as she was devoted to the research of these diseases.

###### 

Clinical details of patients with sarcoidosis.

                                                                                  Total[⁎](#tf0005){ref-type="table-fn"}   Male       Female       
  ------------------------------------------------------------------------------- ---------------------------------------- ---------- ------------ ------------
  Patients                                                                        146                                      (100.0%)   56 (38.4%)   90 (61.6%)
  Age (years, mean ± SD)                                                          46                                       ± 12.7     40 ± 11.8    50 ± 11.9
  Age of onset (years, mean ± SD)                                                 45                                       ± 12.5     39 ± 12.1    48 ± 11.4
                                                                                                                                                   
  *Disease stage*                                                                                                                                  
  0                                                                               10                                       (6.8%)     2 (1.4%)     8 (5.5%)
  I                                                                               64                                       (43.8%)    22 (15.1%)   42 (28.8%)
  II                                                                              52                                       (35.6%)    22 (15.1%)   30 (20.5%)
  III                                                                             15                                       (10.3%)    5 (3.4%)     10 (6.8%)
  IV                                                                              5                                        (3.4%)     5 (3.4%)     0 (0.0%)
                                                                                                                                                   
  *Smoking*                                                                                                                                        
  Yes                                                                             102                                      (69.9%)    27 (18.5%)   75 (51.4%)
  No                                                                              31                                       (21.2%)    21 (14.4%)   10 (6.8%)
  Ex                                                                              13                                       (8.9%)     8 (5.5%)     5 (3.4%)
                                                                                                                                                   
  *Diagnostic tests*                                                                                                                               
  Biopsy (of non-caseating epitheloid cell granulomas in tissue/organ affected)   135                                      (92.5%)    45 (30.8%)   90 (61.6%)
  Lymph nodes                                                                     32                                       (21.9%)    10 (6.8%)    22 (15.1%)
  Skin                                                                            27                                       (18.5%)    5 (3.4%)     22 (15.1%)
  Lung                                                                            13                                       (8.9%)     4 (2.7%)     9 (6.2%)
  Endrobrochial                                                                   31                                       (21.2%)    12 (8.2%)    19 (13.0%)
  Transbronchial                                                                  32                                       (21.9%)    14 (9.6%)    18 (12.3%)
  Clinical-radiological                                                           54                                       (37.0%)    27 (18.5%)   27 (18.5%)
  Hypercalciuria                                                                  35                                       (24.0%)    19 (13.0%)   16 (11.0%)
  Heart involvment                                                                9                                        (6.2%)     3 (2.1%)     6 (4.1%)
  Eye involvment                                                                  9                                        (6.2%)     2 (1.4%)     7 (4.8%)
  Skin                                                                            32                                       (21.9%)    6 (4.1%)     26 (17.8%)
  Löfgren                                                                         27                                       (18.5%)    11 (7.5%)    16 (11.0%)
  Nervous system                                                                  2                                        (1.4%)     0 (0.0%)     2 (1.4%)
  Patients with relapses                                                          36                                       (24.7%)    14 (9.6%)    22 (15.1%)
  Follow-up available \> 2 years (average 5 years)                                121                                      (82.9%)    43 (29.5%)   78 (53.4%)
  FVC%                                                                            99                                       ± 20       93 ± 23      102 ± 17
  FEV1%                                                                           94                                       ± 21       90 ± 23      96 ± 20
  DLCO%                                                                           83                                       ± 24       85 ± 23      82 ± 25

The percentages are based on total number of samples.

###### 

List of variants and genotype frequencies in sarcoidosis and control groups.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Residue            Variation ID (dbSNP)   Exon   Nucleotide (MAF)   SIFT          PolyPhen             PROVEAN       PMut           EX_SKIP              Genotype   Sarcoidosis (*n*:146), counts (frequency)   Controls (*n*:90), counts (frequency)   *p*-value^⁎^
  ------------------ ---------------------- ------ ------------------ ------------- -------------------- ------------- -------------- -------------------- ---------- ------------------------------------------- --------------------------------------- --------------
  H60H\              rs28362683             2      C/T(0.133)         \-            --                   --            --             Yes                  CC\        127 (86.9%)\                                85 (94.44%)\                            0.44\
  c.180C/T                                                                                                                                                 CT\        19 (13.01%)\                                4 (4.44%)\                              0.045\
                                                                                                                                                           TT         0 (0%)                                      1 (1.11%)                               0.38

  W94R\              rs28362682             2      A/T(0.1327)        Tolerated     Benign               Neutral       Pathological   No                   TT\        127 (86.9%)\                                89 (98.88%)\                            0.21\
  c.280A/T                                                                                                                                                 TA\        16 (10.96%)\                                1 (1.11%)\                              0.0088\
                                                                                                                                                           AA         3 (2.05%)                                   0 (0%)                                  0.29

  D118N\             rs143211074            2      C/T(0.003)         Deleterious   Possibly damaging    Deleterious   Neutral        Same chance          GG\        144 (98.63%)\                               90 (100%)\                              0.92\
  c.352G/A                                                                                                                                                 GA\        2 (1.4%)\                                   0 (0%)\                                 0.52\
                                                                                                                                                           AA         0 (0%)                                      0 (0%)                                  1

  A142P\             NOVEL                  2      C/G                Tolerated     Possibly damaging    Deleterious   Neutral        Same chance          GG\        145 (99.3%)\                                90 (100%)\                              1\
  c.424G/C                                                                                                                                                 GC\        1 (0.68%)\                                  0 (0%)\                                 1\
                                                                                                                                                           CC         0 (0%)                                      0 (0%)                                  1

  G143D\             rs115653647            3      C/T(0.037)         Deleterious   Probably damaging    Deleterious   Neutral        No                   GG\        145 (99.3%)\                                90 (100%)\                              1\
  c.428G/A                                                                                                                                                 GA\        1 (0.68%)\                                  0 (0%)\                                 1\
                                                                                                                                                           AA         0 (0%)                                      0 (0%)                                  1

  G145G\             rs57116766             3      C/A(0.132)         --            --                   --                           No                   GG\        145 (99.3%)\                                89 (98.88%)\                            1\
  c.435G/T                                                                                                                                                 GT\        0 (0%)\                                     1 (1.11%)\                              0.38\
                                                                                                                                                           TT         1 (0.68%)                                   0 (0%)                                  1

  S149N\             rs60263670             3      C/T(0.138)         Tolerated     Possibly damaging    Neutral       Neutral        No                   GG\        145 (99.3%)\                                89 (98.88%)\                            1\
  c.446G/A                                                                                                                                                 GA\        0 (0%)\                                     1\                                      0.38\
                                                                                                                                                           AA         1 (0.68%)                                   0 (0%)                                  1

  S149T\             NOVEL                  3      G/C                Tolerated     Benign               Neutral       Neutral        No                   GG\        145 (99.3%)\                                90 (100%)\                              1\
  c.446G/C                                                                                                                                                 GC\        1 (0.68%)\                                  0 (0%)\                                 1\
                                                                                                                                                           CC         0 (0%)                                      0 (0%)                                  1

  T165I\             rs78587369             3      G/A(0.032)         Tolerated     Possibly damaging    Neutral       Pathological   Yes                  CC\        144 (98.6%)\                                89 (98.88%)\                            1\
  c.494C/T                                                                                                                                                 CT\        2 (1.37%)\                                  1 (1.11%)\                              1\
                                                                                                                                                           TT         0 (0%)                                      0 (0%)                                  1

  P171P\             rs59129682             3      T/A(0.133)         --            --                   --            --             No                   AA\        141 (96.57%)\                               89 (98.88%)\                            0.85\
  c.513A/T                                                                                                                                                 AT\        4 (2.74%)\                                  0 (0%)\                                 0.16\
                                                                                                                                                           TT         1 (0.68%)                                   1 (1.11%)                               1

  R181Q\             rs28362681             3      C/T(0.133)         Tolerated     Benign               Neutral       Pathological   No                   GG\        141 (96.57%)\                               89 (98.88%)\                            0.85\
  c.542G/A                                                                                                                                                 GA\        4 (2.74%)\                                  0 (0%)\                                 0.16\
                                                                                                                                                           AA         1 (0.68%)                                   1 (1.11%)                               1

  K196E\             rs2076523              3      T/C(0.370)         Tolerated     Benign               Neutral       Neutral        No                   AA\        108 (73.97%)\                               73 (81.11%)\                            0.49\
  c.586A/G                                                                                                                                                 AG\        38 (26.03%)\                                15 (16.66%)\                            0.13\
                                                                                                                                                           GG         0 (0%)                                      2 (2.22%)                               0.14

  A202V\             rs28362680             3      C/T/G/A(0.170)     Tolerated     Benign               Neutral       Neutral        Yes                  CC\        139 (95.2%)\                                87 (96.665)\                            0.92\
  c.605C/T                                                                                                                                                 CT\        6 (4.1%)\                                   1 (1.11%)\                              0.26\
                                                                                                                                                           TT         1 (0.68%)                                   2 (2.22%)                               0.56

  A202A\             rs147483338            3      C/T                                                                                No                   GG\        145 (99.3%)\                                90 (100%)\                              1\
  c.606G/A                                                                                                                                                 GA\        1 (0.68%)\                                  0 (0%)\                                 1\
                                                                                                                                                           AA         0 (0%)                                      0 (0%)                                  1

  R209R\             rs60036207             3      C/T(0.133)         --            --                   --            --             No                   GG\        140 (95.89%)\                               89 (98.88%)\                            0.77\
  c.627G/A                                                                                                                                                 GA\        4 (2.74%)\                                  0 (0%)\                                 0.16\
                                                                                                                                                           AA         1 (0.68%)                                   1 (1.11%)                               1

  N210N\             rs78107756             3      G/A(0.038)         --            --                   --            --             Yes                  CC\        144 (98.6%)\                                88 (97.77%)\                            1\
  c.630C/T                                                                                                                                                 CT\        2 (1.36%)\                                  2 (2.22%)\                              0\
                                                                                                                                                           TT         0 (0%)                                      0 (0%)                                  1

  E242G\             Novel                  4      T/C                Tolerated     Possibly damaging)   Deleterious   Neutral        Yes                  AA\        145 (99.31%)\                               90 (100%)\                              1\
  c.725A/G                                                                                                                                                 AG\        1 (0.68%)\                                  0 (0%)\                                 1\
                                                                                                                                                           GG         0 (0%)                                      0 (0%)                                  1

  E279E\             rs41333546             5      C/T (0.032)        --            --                   --            --             No                   GG\        143 (97.9%)\                                87 (96.665)\                            0.92\
  c.837G/A                                                                                                                                                 GA\        3 (2.05%)\                                  2 (2.22%)\                              1\
                                                                                                                                                           AA         0 (0%)                                      1 (1.11%)                               0.38

  R281K\             rs41355746             5      C/T(0.032)         Tolerated     Probably damaging    Neutral       Neutral        No                   GG\        143 (97.9%)\                                87 (96.665)\                            0.92\
  c.842G/A                                                                                                                                                 GA\        3 (2.05%)\                                  2 (2.22%)\                              1\
                                                                                                                                                           AA         0 (0%)                                      1 (1.11%)                               0.38

  D283V\             rs34423804             5      T/A(0.038)         Tolerated     Benign               Neutral       Pathological   Yes                  AA\        143 (97.9%)\                                87 (96.665)\                            0.92\
  c.848A/T                                                                                                                                                 AT\        3 (2.05%)\                                  1 (1.11%)\                              1\
                                                                                                                                                           TT         0 (0%)                                      2 (2.22%)                               0.14

  M295V\             rs41417449             5      T/C(0.032)         Tolerated     Benign               Neutral       Neutral        Yes                  AA\        145 (99.31%)\                               88 (97.77%)\                            0.92\
  c.883A/G                                                                                                                                                 AG\        1 (0.68%)\                                  2 (2.22%)\                              0.56\
                                                                                                                                                           GG         0 (0%)                                      0 (0%)                                  1

  E307E\             rs41392447             5      C/T(0.032)         --            --                   --            --             No                   GG\        143 (97.9%)\                                87 (96.665)\                            0.92\
  c.921G/A                                                                                                                                                 GA\        3 (2.05%)\                                  2 (2.22%)\                              1\
                                                                                                                                                           AA         0 (0%)                                      1 (1.11%)                               0.38

  V313V\             rs2076529              5      T/C(0.365)         --            --                   --            --             Yes                  AA\        93 (63.7%)\                                 67 (74.44%)\                            0.27\
  c.939A/G                                                                                                                                                 AG\        50 (34.24%)\                                22 (24.44%)\                            0.18\
                                                                                                                                                           GG         3 (2.05%)                                   1 (1.11%)                               0.38

  S334L\             rs28362679             5      G/A(0.019)         Deleterious   Probably damaging    Deleterious   Neutral        Yes                  CC\        122 (83.56%)\                               79 (87.77%)\                            0.70\
  c.1001C/T                                                                                                                                                CT\        23 (15.75%)\                                11 (12.22%)\                            0.58\
                                                                                                                                                           TT         1 (0.68%)                                   0 (0%)                                  1

  D336N\             rs41441651             5      C/T(0.032)         Tolerated     Possibly damaging    Neutral       Neutral        WT/MUT same chance   GG\        143 (97.9%)\                                88 (97.77%)\                            1\
  c.1006G/A                                                                                                                                                GA\        3 (2.95%)\                                  1 (1.11%)\                              0.38\
                                                                                                                                                           AA         0 (0%)                                      1 (1.11%)                               0.38

  Q350Q\             rs9268480              6      C/T(0.201)         --            --                   --            --             No                   GG\        113 (77.39%)\                               68 (75.55%)\                            0.84\
  c.1050G/A                                                                                                                                                GA\        32 (21.92%)\                                18 (20%)\                               0.76\
                                                                                                                                                           AA         1 (0.68%)                                   4 (4.44%)                               0.072

  S360G\             rs2076530              6      T/C(0.377)         Tolerated     Benign               Neutral       Neutral        Yes                  AA\        86 (58.9%)\                                 51 (56.66%)\                            0.83\
  c.1078A/G                                                                                                                                                AG\        55 (37.67%)\                                27 (30%)\                               0.31\
                                                                                                                                                           GG         5 (3.42%)                                   12 (13.33)                              0.0062

  L366L\             rs76868526             6      G/A(0.032)         --            --                   --            --             Yes                  CC\        143 (97.9%)\                                89 (98.88%)\                            0.92\
  c.1096C/T                                                                                                                                                CT\        3 (2.95%)\                                  1 (1.11%)\                              0.38\
                                                                                                                                                           TT         0 (0%)                                      0 (0%)                                  1

  P379L\             rs28362678             6      G/A(0.159)         Tolerated     Benign               Neutral       Pathological   No                   CC\        124 (84.93%)\                               74 (82.22%)\                            0.77\
  c.1136C/T                                                                                                                                                CT\        21 (14.38%)\                                15 (16.66%)\                            0.72\
                                                                                                                                                           TT         1 (0.68%)                                   1 (1.11%)                               1

  M380I\             rs28362677             6      C/T(0.158)         Tolerated     Benign               Neutral       Neutral        WT/MUT same chance   GG\        124 (84.93%)\                               74 (82.22%)\                            0.77\
  c.1140G/A                                                                                                                                                GA\        22 (15.068%)\                               16 (17.77%)\                            0.60\
                                                                                                                                                           AA         0 (0%)                                      0 (0%)                                  1

  P393Q\             rs41521946             6      G/T(0.121)         Tolerated     Benign               Neutral       Neutral        Same                 CACA\      124 (84.93%)\                               74 (82.22%)\                            0.77\
  c.1178-1179CA/AG                                                                                                                                         CAAG\      21 (14.38%)\                                16 (17.77%)\                            0.59\
                                                                                                                                                           AGAG       1 (0.68%)                                   0 (0%)                                  1

  S404S\             rs41449245             6      T/G(0.158)         --            --                   --            --             Yes                  AA\        123 (84.24%)\                               74 (82.22%)\                            0.84\
  c.1212A/C                                                                                                                                                AC\        23 (15.75%)\                                16 (17.77%)\                            0.73\
                                                                                                                                                           CC         0 (0%)                                      0 (0%)                                  1

  S406A\             NOVEL                  6      T/G                Tolerated     Possibly Damaging    Neutral       Neutral        No                   TT\        144 (98.6%)\                                90 (100%)\                              0.92\
  c.1215 T/G                                                                                                                                               TG\        2 (29.2%)\                                  0 (0%)\                                 0.52\
                                                                                                                                                           GG         0 (0%)                                      0 (0%)                                  1

  G412C\             NOVEL                  6      G/T                Deleterious   Probably damaging    Neutral       Pathological   Yes                  GG\        144 (98.6%)\                                90 (100%)\                              0.92\
  c. 1234G/T                                                                                                                                               GT\        2 (29.2%)\                                  0 (0%)\                                 0.52\
                                                                                                                                                           TT         0 (0%)                                      0 (0%)                                  1

  H414H\             rs41535850             6      G/A(0.158)         --            --                   --            --             Yes                  CC\        123 (84.24%)\                               77 (85.55%)\                            0.92\
  c.1242C/T                                                                                                                                                CT\        23 (14.75%)\                                12 (13.33%)\                            0.72\
                                                                                                                                                           TT         0 (0%)                                      1 (1.11%)                               0.38

  A430D\             NOVEL                  6      C/A                Tolerated     Possibly damaging    Neutral       Pathological   Yes                  CC\        145 (99.31%)\                               90 (100%)\                              1\
  c.1289C/A                                                                                                                                                CA\        1 (0.68%)\                                  0 (0%)\                                 1\
                                                                                                                                                           AA         0 (0%)                                      0 (0%)                                  1

  E454C\             rs28362675             6      C/G/A(0.03)        Deleterious   Probably damaging    Neutral       Pathological   No.                  GG\        142 (97.26%)\                               90 (100%)\                              0.77\
  c.1360G/T                                                                                                                                                GT\        4 (2.74%)\                                  0 (0%)\                                 0.16\
                                                                                                                                                           TT         0 (0%)                                      0 (0%)                                  1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BTNL2* gene sequence: NM_019602.1 (ENSG00000454136), numbering according to HGVS nomenclature-cDNA sequence with + 1 corresponding to the A of the ATG translation initiation codon. \**p*-values calculated by double-sided Fisher\'s exact test.

###### 

Genotype and clinical characteristics of patients carrying probable risk variants.

  Case   Main variant   Other risk variants\*                         Sex/age (years)   Disease stage      Other clinical characteristics                                        DLCO %^†^
  ------ -------------- --------------------------------------------- ----------------- ------------------ --------------------------------------------------------------------- -----------
  38     p.S360G                                                      F/52              Stage 0            Uveitis                                                               81
  103    p.S360G        p.T165I, p.D283V, p.S334L, p.G454C, p.M295V   M/25              Stage 0            Löfgren                                                               94
  7      p.S360G                                                      F/56              Stage 0                                                                                  81
  77     p.S334L        p.G412C                                       F/55              Stage 0            Skin granulomas                                                       91
  96     p.S334L                                                      F/49              Stage 0            Skin granulomas                                                       100
  21     p.A202V        p.A202V                                       F/59              Stage 0            Skin granulomas                                                       85
  2033   p.S360G                                                      F/38              Stage I            Hyperalciuria, Löfgren                                                93
  221    p.S360G                                                      F/65              Stage I            Löfgren                                                               66
  119    p.S360G        p.A430D                                       M/34              Stage I            Uveitis, hypercalciuria                                               95
  2019   p.S360G        p.D118N, p.A148P                              F/28              Stage I            Parotid gland swelling                                                86
  180    p.S360G                                                      M/40              Stage I, Löfgren   Relapse                                                               90
  97     p.S360G                                                      F/50              Stage I                                                                                  69
  102    p.S360G                                                      F/49              Stage I                                                                                  123
  25     p.S360G                                                      F/72              Stage I                                                                                  89
  2035   p.S360G                                                      F/47              Stage I                                                                                  109
  95     p.S360G                                                      F/51              Stage I            Skin granulomas                                                       113
  2026   p.S360G                                                      M/64              Stage I            Skin granulomas                                                       121
  149    p.S360G                                                      M/30              Stage I            Hyperalciuria                                                         74
  2028   p.S360G        p.A202V                                       F/55              Stage I            Skin granulomas, heart, pulmonary hypertension, nodulous erythema     91
  2027   p.S360G                                                      F/40              Stage I            Heart, hypercalciuria, hypocalcemia                                   77
  33     p.S360G                                                      F/25              Stage I            Skin granulomas                                                       79
  19     p.S360G        p.S334L                                       F/27              Stage I            Skin granulomas, heart, nodulous erythema, relapse                    82
  71     p.S360G                                                      F/62              Stage I            Löfgren                                                               83
  178    p.S360G        p.S360G                                       F/39              Stage I            Löfgren, parotid gland swelling                                       111
  166    p.S360G                                                      M/27              Stage I            Hypercalciuria                                                        100
  165    p.S360G        p.S360G                                       F/55              Stage I                                                                                  93
  90     p.S360G        p.G143D, p.A202V                              M/36              Stage I            Löfgren                                                               102
  2020   p.S360G                                                      M/44              Stage I            Hypercalciuria                                                        79
  18     p.S360G                                                      M/43              Stage I            Pleural fluid, hypercalciuria, hepatomegaly                           128
  274    p.S360G        p.G412C                                       F/27              Stage I            Hypercalciuria                                                        100
  37     p.S360G                                                      M/21              Stage I                                                                                  97
  50     p.S360G                                                      M/58              Stage I                                                                                  107
  167    p.S334L                                                      M/36              Stage I            Löfgren, skin granulomas                                              86
  54     p.S334L                                                      M/36              Stage I            Löfgren, nodulous erythema, skin granulomas                           118
  42     p.S334L                                                      F/54              Stage I            Hypercalciuria                                                        96
  101    p.S334L                                                      F/47              Stage I            Löfgren                                                               88
  64     p.S334L                                                      F/37              Stage I            Nodulous erythema, skin granulomas, CNS, heart, relapse               115
  86     p.S334L                                                      F/41              Stage I            Löfgren                                                               102
  181    p.A202V                                                      F/60              Stage I            Löfgren, nodulous erythema, hypercalciuria, skin granuloma, relapse   98
  227    p.S360G                                                      F/54              Stage I            Hypercalciuria, uveitis                                               67
  2034   p.S360G                                                      M/35              Stage I            Hypercalciuria, uveitis, relapse                                      98
  194    p.S360G                                                      M/41              Stage I                                                                                  80
  63     p.S360G        p.D283V, p.G454C, p.A202V                     M/41              Stage I            Relapse                                                               59
  72     p.S360G                                                      F/46              Stage II                                                                                 54
  2069   p.S360G                                                      M/32              Stage II                                                                                 70
  2068   p.S360G                                                      M/43              Stage II                                                                                 47
  61     p.S360G                                                      M/44              Stage II           Pulmonary hypertension                                                56
  65     p.S360G                                                      F/68              Stage II           Cervical lymph gland swelling                                         82
  2025   p.S360G                                                      M/28              Stage II                                                                                 85
  94     p.S360G                                                      M/41              Stage II           Nodulous erythema                                                     109
  9      p.S360G                                                      M/25              Stage II                                                                                 76
  2054   p.S360G                                                      M/48              Stage II           Heart, hypercalciuria, Löfgren                                        112
  15     p.S360G                                                      F/59              Stage II           Hypercalciuria, nodulous erythema, uveitis, face nodules              74
  39     p.S360G                                                      M/32              Stage II                                                                                 112
  27     p.S360G                                                      F/73              Stage II           Hyperalciuria, hypocalcemia                                           88
  85     p.S360G                                                      M/41              Stage II           Hypercalciuria, hypocalcemia                                          84
  56     p.S360G        p.S360G                                       M/26              Stage II                                                                                 110
  213    p.S360G                                                      M/34              Stage II           Hypercalciuria                                                        104
  52     p.S360G                                                      F/49              Stage II           Pulmonary hypertension, relapse                                       57
  2023   p.S360G        p.A202V                                       M/30              Stage II           Hypogammaglobulinemia, relapse                                        39
  163    p.S360G        p.S360G, p.T165I, p.D283V, p.G454C, p.A202V   F/40              Stage II           Hypercalciuria, hypocalcemia, relapse, pulmonary hypertension         102
  264    p.S334L                                                      F/60              Stage II                                                                                 71
  59     p.S334L                                                      F/71              Stage II           Relapse, nodulous erythrema                                           104
  222    p.S334L                                                      M/32              Stage II           Pulmonary hypertension, relapse                                       84
  17     p.S334L                                                      F/47              Stage II           Nodulous erythema, skin                                               68
  2031   p.S334L                                                      M/32              Stage II           Hypercalciuria, skin                                                  97
  173    p.S334L                                                      F/49              Stage II           Relapse                                                               65
  57     p.S334L                                                      F/29              Stage II                                                                                 73
  239    p.E242G                                                      M/52              Stage II           Hypercalciuria, relapse                                               57
  104    p.S360G        p.S334L                                       M/50              Stage III                                                                                91
  168    p.S360G        p.S360G                                       M/49              Stage III          Relapse                                                               71
  89     p.S360G                                                      F/50              Stage III          Hyperalciuria, relapse                                                60
  60     p.S360G                                                      F/48              Stage III          Uveitis                                                               95
  268    p.S360G                                                      F/48              Stage III                                                                                95
  114    p.S360G        p.D118N                                       M/58              Stage III          Skin granulomas                                                       66
  46     p.S334L                                                      F/50              Stage III                                                                                91
  196    p.S334L                                                      F/58              Stage III                                                                                63
  162    p.S334L                                                      F/39              Stage III          Hypercalciuria, hypocalcemia, skin, relapse                           69
  20     p.S334L                                                      M/39              Stage III          Hypercalciuria, skin granulomas, hypocalcemia, relapse                69
  235    p.S334L        p.S334L                                       F/48              Stage III          Hypercalciuria, heart, relapse                                        87
  78     p.S360G                                                      M/37              Stage IV                                                                                 40
  2029   p.S334L                                                                        Stage IV                                                                                 85
  49     p.G454C                                                      M/40              Stage IV           Hypercalciuria, hypocalcemia, pulmonary hypertension, relapse         102

\*, Variants characterized as probable risk and/or causing exon skipping by the *in silico* method (see Methods); ^†^DLCO: diffuse lung capacity for CO.
